European VC founded 1972, Paris HQ (offices: London, Milan). €4.1bn AUM (2025). 80+ professionals (25 investment partners, 24 nationalities). Backed 500+ portfolio cos; 23 IPOs, 30 M&As (MaxCyte, Flexion Therapeutics, Ascendis Pharma). Capital XI closed €650m (Nov 2025). Active co-investor; leads Series A predominantly. Proprietary AI platform (Sofinnova.ai, 5-yr build). Strong track record in clinical-to-commercial progression.
Investment Focus
Investment Thesis
Seed-to-later-stage life sciences investor. Core focus: biopharma, medtech, industrial biotech, digital medicine, sustainability. Flagship Capital Strategy targets early-stage biopharma/medtech; Crossover Strategy for growth-stage validated companies; Biovelocita accelerator for European biotech spinouts. Hands-on company builders. 7 strategies across value chain. Strong scientific expertise. Lead/cornerstone investor posture. Avoids late-stage pure play venture/non-life sciences.
Interested in connecting?
Visit their website or reach out directly.